OralTox Rapid Fluid 5 Panel Drug Test DOA OralTox Advantages

OralTox Advantages

simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests

This test is not intended for use in screening blood or plasma donors

Influenza A and Influenza B* Turnaround time: 30 minutes* Lab-quality accuracy* No maintenance or service contracts* Easy to run multiple patient tests simultaneously* EUA for use in CLIA-waived point-of-care settings* Accuracy: Influenza A: PPA 96

20 disposable plastic fixed volume pipettes (for whole blood only) packed in one pvc re-sealable bag

OralTox Rapid Fluid 5 Panel Drug Test DOA OralTox AdvantagesModel Drugs Included 5 Panel AMP, COC, METH, OPI, PCP OralTox is a FDA 510(k) cleared patented device that identifies the absence or presence of illicit drugs in minutes. Oral fluid drug testing offers a minimally invasive, observed collection to detect recent drug use with results in minutes. Using oral fluid, the collector can oversee a donor as he or she collects their own oral fluid specimens, reducing the likelihood of tampering or cheating as